Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU2 | Q9Y3R4 | 5/20 | 0.49 |
| ▸ | NEU3 | Q9UQ49 | 4/20 | 0.49 |
| ▸ | NEU4 | Q8WWR8 | 3/20 | 0.49 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SELL | P14151 | 1/20 | 0.41 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24418448 | 1.00 | NEU2 (0.49) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL17297667 | 1.00 | NEU2 (0.49) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL14725954 | 0.90 | NANP (0.41) | NEU2NEU3NEU4NEU1SELL | |
| SCHEMBL12702851 | 0.88 | SELL (0.45) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL12661467 | 0.88 | SELL (0.45) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL12855840 | 0.88 | SELL (0.45) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL13863046 | 0.88 | SELL (0.45) | NEU2NEU3NEU4NEU1LMNA | |
| SCHEMBL24630056 | 0.87 | NEU1 (0.40) | NEU2NEU3NEU4NEU1L3MBTL1 | |
| SCHEMBL19087135 | 0.87 | NEU2 (0.42) | NEU2NEU3NEU4NEU1SELL | |
| SCHEMBL149190 | 0.86 | NEU2 (0.50) | NEU2NEU3NEU4NEU1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280472-A1 | TREATMENT OF PULMONARY FIBROSIS USING INHIBITORS OF NEU1 SIALIDASE | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280472-A1 | TREATMENT OF PULMONARY FIBROSIS USING INHIBITORS OF NEU1 SIALIDASE | NEU1, NEU2, NEU4 | NEU2 2/4885NEU3 4/4885NEU4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.